KR20040033333A - Manufacture method, Various uses and Extracts for The Development of Antihyperlipidemic Functional food materials from Oriental Herbal Medicines - Google Patents

Abstract

PURPOSE: Provided are antihyperlipidemic concentrate of herbal medicines and the manufacturing method and use thereof. The manufactured antihyperlipidemic concentrate or powder has excellent amelioration effects on hyperlipidemia and hypercholesterol. CONSTITUTION: An antihyperlipidemic concentrate of herbal medicines is manufactured by extracting 5-65 wt.% of Crataegus Pinnatifida Bunge, 5-20 wt.% of Salvia miltorrhiza Bunge, 5-20 wt.% of Pleuropterus multiflorus, 5-15 wt.% of Acanthopanax Senticosus, 5-15 wt.% of Bambusae caulis in Taenian, 5-10 wt.% of Chrysanthemum indicum L., 5-10 wt.% of licorice root and 5 wt.% of Schizandra chinensis Baill with water as a solvent, and concentrating the extract thereof under reduced pressure.

Description

Manufacture method, Various uses and Extracts for The Development of Antihyperlipidemic Functional food materials from Oriental Herbal Medicines}

The present invention relates to a concentrate for improving hyperlipidemia by herbal medicine materials, and a method and use of the same. In particular, it is possible to prepare a concentrate and lyophilized powder for improving hyperlipidemia and hyperlipidemia, which has excellent effect of improving hyperlipidemia and high cholesterol, from herbal materials such as hawthorn, red ginseng, red sewage, zao, gamkook, licorice, and Schisandra chinensis.

In Korea, chronic diseases such as hyperlipidemia, atheroslerosis, diabetes, hypertension, etc. are caused by various factors such as economic growth, richness and westernization of diet, and lack of exercise due to automated living. There is an increasing number of adult diseases, that is, non-infectious degenerative diseases.

In particular, the development of various adult diseases due to the increased cholesterol intake has emerged as a serious social problem, each country is focusing on the synthesis of various functional foods and hyperlipidemia treatment to be used with diet to solve this problem.

Hyperlipidemia is a disease in which serum concentrations such as serum lipids, ie, cholesterol, triglycerides (TG), phospholipids, and free fatty acids are increased, and are an important risk factor for atherosclerosis. In addition, it is likely to cause complications such as coronary arteriosclerosis and cerebral infarction such as hypertension, angina pectoris and myocardial infarction.

Until now, a number of compounds exhibiting anti-hyperlipidemic activity have been reported, but most of them have been synthesized by chemical techniques, and in view of the present situation, various side effects of continuous use cannot be avoided.

In order to improve this point, there is a "composition for the prevention and treatment of hyperlipidemia and arteriosclerosis containing hematein" disclosed in Korean Patent Application Publication No. 02-60115 (published in 7.16), but it does not improve hyperlipidemia. There is no good effect.

The development of science and technology is bringing about changes in the lifestyle of human beings, and all disciplines including medicine are continually developing, but oriental medicine has some identity because of its uniqueness. It should be developed and sublimated, the present inventors have developed the present invention to contribute to the basic research foundation for improving national health and research and development of new herbal treatment technology.

Therefore, the present inventors have developed a result of a polite study in view of the above points, the main purpose is to drink from the herbal formulation consisting of Sansa, Dansam, Drip Sewage, Zhao-ga, kill, persimmon, licorice, Schisandra chinensis The present invention provides a concentrate for improving hyperlipidemia, a method for preparing the same, and a method for using the same, wherein the concentrate has the effect of improving the hyperlipidemia and the symptoms of hypercholesterol, or the herbal ingredient which enables the powder to be lyophilized.

In order to achieve the above object, the concentrate having the effect of improving the hyperlipidemia and hypercholesterol symptom by the herbal medicine of the present invention is a sansa, sweet ginseng, drop sewage, zhao ga, kill, persimmon, licorice and schisandra chinensis according to the invention of claim 1 It is characterized in that the herbal extract made by mixing the extract extracted by pouring water (water) with a solvent.

In addition, in order to achieve the above object, the manufacturing method of the concentrate having the effect of improving the hyperlipidemia and hypercholesterol symptoms by the herbal medicine of the present invention is the sansa, dansam, drop sewage, zao, killing, gamgu Putting the herbal ingredients of licorice and Schisandra chinensis into a prepared container; Injecting only pure water corresponding to 20 times the total weight ratio of the herbal ingredient formulation into the container; Decoction of the herbal formulation mixed with water at 95-100 for 2 hours; It characterized in that it comprises a step of obtaining a concentrated liquid by filtration of the hot water solution to filter or sieve (net) having a scale of 200 mesh to obtain a concentrated liquid.

After the step of obtaining the concentrate in the above it is also preferable to perform a freeze-drying step for lyophilizing the concentrate to powder.

Herbal medicine material is characterized in that consisting of the following component ratios.

[5 to 65% by weight of hawthorn; 5-20% by weight of Salvia, 5-20% by weight of drizzle; 5-15% by weight meridian; Kill 5-15%; 5-10% by weight of the country; Licorice 5-10% by weight; Schisandra chinensis 5% by weight]

The concentrate obtained above is added to the production of beverages (soft drinks, drink preparations, etc.), ice creams, dairy products, noodles, sauces, chewing gum, confectionery (candy, jelly, granules). In this case, the addition ratio of the concentrate is preferably 1 to 10% by weight based on the total weight ratio.

Sansa ( Crataegi Fructus ) used in the above "Dried leaves of Crataegus pinnatifida BGE. Var. Typica SCHNEIDER. And related genera of the deciduous tree belonging to the Rose family, has the following pharmacological action.

Antimyocardial ischemic action: Sansa increases blood flow in coronary arteries and reduces oxygen consumption in myocardium. Myocardial ischemia, protective against oxygen deficiency. In addition, it increases blood flow in coronary arteries and reduces oxygen consumption and oxygen utilization in myocardium.

2. Serum lipid lowering, atherosclerosis inhibiting action: lowers total cholesterol and β-lipoprotein levels in serum. It also lowers LDL-C and VLDL-C. It also reduces dose-dependent arterial deposition of cholesterol and cholesterol esters. Sansa activates LCAT (lecithine cholesterol acyl transferase), preventing free cholesterol from depositing easily and preventing atherosclerosis. Ursolic acid is the component used to treat atherosclerosis of the hawthorn.

3. Application: Indigestion, hyperlipidemia, high blood pressure, myocardial infarction, wet dysentery, enteritis, hepatitis, jaundice, menopause, postpartum uterine rehabilitation, etc. If you take ginseng and disagree with it, it will be released by a hawthorn. " have.

Salviae Miltiorrhizae Radix used above is derived from the roots and rhizomes of the perennial herb, Salvia miltiorrhiza BGE. It is harvested in spring and autumn, and is removed and dried in the sun. In the main herbaceous tree, the root skin is red, and the flesh is purple.

Pharmacological action 1. The action on the heart blood flow: Salvia improves cardiac function. Myocardial contractility is increased but myocardial oxygen consumption is not increased, so it is applied to the emergency treatment of myocardial infarction. Salvia increased the blood flow by expanding coronary arteries. Coronary artery disease patients have extended their medication time even after taking long-term medications, and the blood flow index of coronary arteries increases.

2. Anti-thrombotic formation and hemodynamic improvement action: Salvia mildew increases the activity of fibrinolysin and promotes the dissolution of fibroprotein. Therefore, a large dose of Dansam in the vein causes bleeding and prolongs blood clotting time. In vitro, blood clotting can be prolonged by treating the serum with other doses of 20% salvia extract.

Salvia mildew improves the hemodynamic characteristics of fish blood patients. Salvia is effective in patients with ischemic stroke.

3. Peripheral circulation improvement: Peripheral circulatory disorder after symptomatic injection of Ringerdor of Danssam in patients with coronary artery disease. This effect is basically consistent with the clinical effect.

The Polygoni Multiflori Radix used above is dried perennial tubers belonging to the genus Agusta . When leaves fall in winter and winter, cut off both ends and dry. In our country, gourd plants are in circulation and need to be reviewed. Lecithin and hydroxyanthraquinone derivatives include chrysophanol, emodin, physcion, and question. Polygonimitin B and C have recently been isolated.

"1. pharmacological action

Blood lipid lowering, anti-aging action: In the old book, Shoushou was called the black north-jail heat complex retirement age aging (노 年 不 老). "Sewage has a pronounced lipid-lowering effect in several animal models such as rabbits, pigeons, rats and quails. It extends the survival time of pigeons and at the same time increases the ratio of plasma HDL-C and HCL-C / Tc and improves lipid metabolism. And antioxidant activity such as lowering the plasma lipid peroxide content. "In particular, ① lower serum cholesterol, ② reduce or prevent atherosclerosis. ③ increase the coronary blood flow to a light degree, and the protective effect of a constant heart muscle. ④ increases the ability to withstand cold mice, ⑤ thymus atrophy of the old mouse a ache, so you can see that it is involved in immune function. ⑥ promotes the interlocking effect of the intestinal tract is effective for constipation, ⑦ inhibits the development of Mycobacterium tuberculosis and dysentery. In addition, the component sewage contains "anthraquinone derivatives, the main components of which are chrysophanic acid, chrysophanol, emodin, rhein, anthronene, and starch." According to clinical reports, "hyperlipidemia x 0.25mgTlr 3 times a day 2 ~ It took 12 weeks to take effect. "

Zhaoga (刺五加) used in the above ( Acnthopanacis Senticosi ) is dried roots, rhizomes, stems of the Oga family thorns Ogapi (刺五加), the main components include eleutheroside A ~ E. It also contains chlorogenic acid, -sitosterol, betulinicacid, amygdalin, and isofraxidin. According to "pharmacological action"

1. Influence on the cardiovascular system: Zhao expands cerebrovascular vessels and improves cerebral blood flow. Zagaga Outpost aqueous solution increases cardiac vein flow rate, decreases and slows heart rate and suppresses cardiac contraction in rabbits and cats. The effective part of dilating the vein is the part containing water-soluble flavonoids. Zhaoga saponin of the leaf has a clear effect of increasing the intake rate of 86Rb in the heart of the mouse, which means that the blood flow of nutrients in the cardiac organ is obvious.

In vitro, Zhaoga ethanol extract has inhibitory effect on ADP and collagen, which causes platelet aggregation. In experiments with rats and rabbits, intravenous Zaoga showed antiplatelet aggregation. It also correlates with antiplatelet aggregation and the amount of intracellular Ca ++ as it rises in plasma. This action can be used as an important mechanism for the treatment of angina and cerebral thrombosis. "

As used above, " Bambusaceae Caulis " is a perennial evergreen wood stem of the bamboo family (Bambusaceae). ) Middle layer, dried, and in China, Bamysa tuldoides MUNRO. "The outer shell is removed from the fresh stems of the plant, and the greenish middle layer is made into a thread-like or thin line-shape.""Characteristics is an irregular thread and long thread-shaped flakes, uneven in width and thickness, pale green or yellowish green. The body is light and coarse. And the vagina is soft, tough and elastic. "

Chrysanthemi Flos , used above, is a dried perennial herb, a chrysanthemum belonging to the Asteraceae, which is collected when the flowers bloom in full bloom between September and November and dried in the shade or dried on fire. It may dry in the sun after it is heated.

In addition, according to the pharmacological action "1. Coronary blood flow increase action: chrysanthemum extract acts to expand the coronary artery of the extraction heart of rabbits to increase the blood flow of coronary artery. There is no effect on myocardial contractility. Extraction of 白菊) or extraction of guinea pigs shows the effect of dilatating the coronary arteries of the heart When a large dose is injected into the heart, coronary blood flow increases by about 40% and myocardial oxygen consumption increases by 27%.

2. Serum lipid lowering action

Chrysanthemum alone or in combination with hyssop, jihwang (地 黄), and acid ((), increases the activity of glutathoine peroxidase in the blood of mice and decreases the content of lipid peroxide. It affects metabolism, which inhibits the synthesis of cholesterol in the liver and at the same time promotes the breakdown of cholesterol, which greatly affects the activity of cholesterol.

Applications

1. It is used for coronary artery disease, hypertension, arteriosclerosis, gastritis, bronchitis, tonsillitis, conjunctivitis and chronic colitis.

Licorice (Glycyrrhizae Rdix) used in the above is the perennial herb European licorice (light fruit licorice) Glycyrrhiza glabra L. and Manchurian licorice (Liquorice) G. uralensis FISCH. Or dried roots and rhizomes of other cognate plants. Collected in spring and autumn to remove beard roots and dry in the sun.

This drug was named because it is sweet. It is also called 'national road', meaning that it harmonizes the medicines used together like the elders of the country, and sweetness has a strong effect of relaxing and anger.

Among the pharmacological actions, anti-ulcer activity, licorice powder, licorice extract, glycyrrhetinec acid, liquiritine, liquiritigenin isoliquiritine, and FM100 (refining methanol extract containing less glycyrrhizic acid) have inhibitory effects on several experimental ulcer models in rats. Not only does it improve, but it also quickly heals the ulcer. Licorice water extract also protects the gastric mucosa by increasing hexoamine in gastric mucosa.

Schizandriae Fructus , used in the above, is the dried fruit of Schizandriae Fructus , Schizandriae Fructus , Schizandriae Fructus . In China, S. chinensis BAILLON is called Schisandra chinensis, and S. spenanther REHD. et WILS. is referred to as South Sumija (南 五味子). Collect it after rising and dry it in the sun or heat it and use it to dry in the sun.

"1. Action on the cardiovascular system: Schizandra has the effect of dilation of blood vessels. Schizandrin, deoxy schizandrin, etc. have a suppressive effect on the contraction of the dog-extracted artery induced by PGF2, CaCl2 and norepinephrine, and the extraction heart of the guinea peak Increased coronary blood flow in anesthetized dogs North Omija (北 五味子) improves the function of cardiomyocytes and heart and kidney arteries of rabbits, increases myocardial metabolic enzyme activity and improves myocardial nutrition.

Hereinafter, more preferable embodiment of this invention is described in detail.

First, the manufacture example of this invention is demonstrated.

<Production example>

Sansa, red ginseng, drop sewage, zhaoga, kill, prepared by pre-treatment work in order to prepare the raw materials of herbal medicine, gamgu, licorice, and Schisandra chinensis, in order Put it in. The content of the herbal medicine is 5 ~ 65% by weight of sansa; Salviae 5-20 wt%; 5-20 wt% of dropwise water; 5-15 weight percent meridian; Kill 5-15%; 5-10% by weight of the country; Licorice 5-10% by weight; 5 wt% of Schisandra chinensis was added.

Inside the decoction machine into which the herbal material is added, only pure water equal to 20 times the total weight ratio of the herbal compound is introduced into the decoction machine. At this time, it is preferable to use distilled water containing no impurities as the water used.

The herbal compound mixed with water is subjected to the application of the hot water in the hot water heater. The temperature rises to about 95 -100 ° C., and the hot water is hot water for 2 hours when the hot water boils to obtain the hot water.

The hot water obtained in the above step is filtered through a filter or sieve having a mesh size of 200 mesh and concentrated under reduced pressure using a general vacuum concentrator to obtain a concentrate of 50 to 80 Brix. The concentrate is then packaged and sold in pouches or cans of approximately 200ml for easy drinking. In packaging the concentrate, flavors or sugars may be added for flavor. The packaging pouch or can is sterilized in advance.

In addition, the concentrate obtained as described above can be lyophilized using a common freeze dryer to be supplied as a powder (Powder) state.

Preferred embodiments for obtaining the concentrate of the present invention prepared as above are as follows.

Example 1

Put the raw materials of Sansa, Dansam, Drip Sewage, Zhaoga, Kill, Gamkook, Licorice, and Schisandra chinensis into the ready-to-use water heater, and then add distilled water equal to 20 times the total weight ratio of the herbal ingredients in the water heater. The herbal preparation of the hot water machine was plunged as 100 for 2 hours to obtain a hot water solution. The obtained liquid solution was concentrated on a reduced pressure after filtration through a filter paper having a grid size of 200 mesh, thereby obtaining a concentrate for improving hyperlipidemia of 50 Brix. The added amount of Sansa, sweet ginseng, dripping sewage, Zhao ga, kill, persimmon soup, licorice and Schisandra chinensis were formulated and blended as shown in Table 1 below.

<Examples 2 to 7>

Examples 2 to 7 also varying only the composition ratio of the herbal ingredients as shown in Table 1 below to obtain a concentrate for improving hyperlipidemia in the same manner as in Example 1. In addition, the test results of the concentrate for improving constipation obtained from the above Examples (1-7) were the same as the following test examples.

<Medicinal material composition ratio> division Example <Unit: wt%> One 2 3 4 5 6 7 Sansa 65 55 40 30 20 10 5 Salvia 5 10 10 15 15 20 20 Droopy 5 10 10 15 15 15 20 Zhao 5 5 10 10 15 15 15 Kill 5 5 10 10 10 15 15 Country 5 5 10 10 10 10 10 licorice 5 5 5 5 10 10 10 Schisandra 5 5 5 5 5 5 5

Experimental Example 1

1) Experiment animal

As experimental animals, Sprague-Dawley male rats, 6 weeks old, were purchased from Samtaco Co., Ltd., and weighed 200 ± 20g.They were adapted to the laboratory environment for one week with sufficient solid feed and water. Unless otherwise, it was carried out at 24 ± 2 ° C.

2) materials and reagents

① The materials used in this experiment were purchased from Gyeongdong Market in Jegi-dong, Dongdaemun-gu, Seoul and used. In addition, the prescription used in the experimental example was founded by the College of Oriental Medicine, Kyung Hee University, the amount of one book was the amount corresponding to Example 1.

② As the reagent used in the experiment, Triton WR-1339 used Sigma (Sigma Chemical, U.S.A) and Lovastatin (Mevaco Co., Ltd.).

3) Experimental group and sample administration

The experimental animals were treated with the normal feed group (hereinafter, normal group, nomal group), Triton administration group (hereinafter, control group, control group), sample administration group (hereafter, experimental group. Sample group, hyperlipidemic concentrate, JH1004 administration group) 100 mg, 1000 mg. Positive control group (hereinafter, statin-based hyperlipidemic drugs-Lovastain): Mevaco tablets were divided into 5 groups, total 100mg, and 6 rats were included in one group. The normal group was fed freely for 7 days while fully administering the general feed, and the sample administration group was fed orally once daily for 7 days according to the dose. The experimental group and the sample solution (hyperlipidemic concentrate) administration were divided into the normal control group and the Examples (1-7). Six rats were taken as one group. The experimental group was converted to the rat weight ratio of the prepared sample, orally administered daily, and the normal control group was administered 2ml of saline solution in the same manner as the sample administration group.

4) Effect on Triton WR-1339 administration-induced hyperlipidemic rat condition model

Six groups of rats were fasted for 16 hours, followed by injection of 200 mg / kg of Triton WR-1339 (Tyloxapol) into the tail vein to induce hyperlipidemia. As a positive control drug, lovastatin 100mg / kg was used for comparison.

Serum is separated by centrifuging the collected blood for 30 minutes at 4,000 rpm. Serum lipid triglyceride (hereinafter referred to as TG), total cholesterol (hereinafter referred to as TC), phospholipid (hereinafter referred to as PL), HDL-cholesterol, LDL-cholesterol content and transaminsae enzyme activity (hereinafter referred to as GOT and GPT) were measured.

5) Measurement of Serum Components

① Total cholesterol content measurement

The total cholesterol content in serum was measured by Cholesterol C-Test Kit (Wako Chemical Industries, Ltd., Japan) by enzamatic COD-PAP method.

② Determination of triglyceride content

Serum triglyceride content was measured by triglyceride GIIKit (Wako Chemical Industries, Ltd., Japan) by GPO-PAP method.

③ Phospholipid content measurement

Phospholipid content in serum was measured by Phospholipid B-Test Kit (Wako chemical Industries, Ltd., Japan) by the enzamatic COD-PAP method.

④HDL-cholesterol content measurement

Serum HDL-cholesterol content was measured by Heparine-Mn binding sedimentation method, and HDL-cholesterol Test Kit (Wako Chemical Industries, Ltd., Japan) was used.

⑤ LDL-cholesterol content measurement

The serum LDL-cholesterol content was measured by an enzyme method such as Mainard, and the LDL-cholesterol Test Kit (Wako Chemical Industries, Ltd., Japan) was used.

⑥ Measurement of blood AST content

Aspartate aminotransferase (AST) activity was absorbed at 340 nm by adding 100 μl of serum to Hepes buffer containing pH of 1 ml of L-aspartate 200mM, 2-oxoglutarate 12mM, 600Unit / L malate dehydrogenase and 0.25mM NADH (pH 7.8). It was measured by the hourly reduction rate of.

⑦ Measurement of ALT content in blood

The activity of Alanine aminotransferase (ALT) was determined by adding 100 μl of serum to Hepes buffer containing pH of 1 ml of L-alanine 400 mM, 2-oxoglutarate 12 mM, 2,000 Unit / L acetate dehydrogenase and 0.25 mM NADH (pH 7.4). The hourly decrease in absorbance was measured.

6) Statistics processing

In the above statistical process, the mean value for the mutual comparison between the experimental groups of the results obtained from the experiments was recorded as mean ± standard error (Mean ± SEM). Significance was recognized when the -value was less than 0.05.

7) Experimental results

In experimental hyperlipidemic condition models, a surfactant such as Triton WR-1339 or Tween 80, which is a model of endogenous hyperlipidemia, is used to elevate cholesterol and triglyceride in the blood, which affects enzymes involved in cholesterol synthesis and inhibits triglyceride excretion. It has been reported that experimental hyperlipidemic condition models are induced. Samples were orally administered to serum triglyceride, total cholesterol, phospholipid, HDL-cholesterol, LDL-cholesterol content and transaminsae enzyme activity.

1. Total cholesterol (TC) content in blood

First, the serum TC content of rats in Triton WR-1339 treated control group was 270.67 ± 88.73mg / dl, which was significantly higher than that of untreated normal group 85.33 ± 15.93mg / dl. JH 1004-100mg and 1000mg were 119.00 ± 38.19mg / dl and 116.67 ± 34.42mg / dl, respectively. In the positive comparison drug lovastatin 100mg / kg group, the synergistic inhibitory effect was observed at 329.83 ± 124.63mg / dl, but it was not significant (see Table 2).

Effect of JH1004 on serum Total cholesterol level in hyperlipidemic rats induced by Triton WR-1339 Group Dose No.of Serum total cholesterol protection (mg / kg, p.o) animals levels (mg / dl) (%) Normal - 6 85.33 ± 15.93 - Control - 6 270.67 ± 88.73 ### 100% Sample A 100 6 119.00 ± 38.19 ** 81.8% Sample B 1,000 6 116.67 ± 34.42 ** 83.1% Lovastatin 100 6 329.83 ± 124.63 -31.9%

* Each value is the mean ± standard error of 6 animals

The total cholesterol inhibition value is a% value calculated as 100x (control value-value of control group) / control value-value of normal group).

# Valid numeric ranges for normal group (#: p <0.05, ##: p <0.01 and ###: p <0.001)

* Significant range of numbers for the control group (*: p <0.05 and **: p <0.01)

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

2.triglyceride content in blood

The triglyceride content in the normal group was significantly increased to 1164.50 ± 29.79mg / dl in the control group compared to 89.50 ± 1.99mg / dl, and the experimental group was 208.00 ± 95.07mg / dl in the JH1004-100mg group and JH1004-1,000mg group. 160.33 ± 77.89mg / dl showed a significant synergistic inhibitory effect compared to the control. In the positive comparison drug lovastatin 100mg / kg group, an upward inhibition of 1146.17 ± 644.84mg / dl was observed, but there was no significance (see Table 3).

Effects of JH1004 on Serum Triglyceride Level in Hyperlipidemic Rats induced by Triton WR-1339 Group Dose No. of Serum triglyecride protection (mg / kg, p.o.) animals levels (mg / dl) (%) Normal - 6 89.50 ± 31.99 - Control - 6 1164.50 ± 729.79 ### 100% Sample A 100 6 208.00 ± 95.07 ** 89.0% Sample B 1,000 6 160.33 ± 77.89 ** 93.4% Lovastatin 100 6 1146.17 ± 644.84 1.7%

* Each value is the mean ± standard error of 6 animals.

Triglyceride inhibition is a% value calculated as 100x (control value-sample value) / control value-normal value).

# Valid numeric ranges for normal group

* Significant range of numbers for the control group (*: p <0.05 and **: p <0.01)

Normal: non-killing group,

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

3. Phospholipid Content in the Blood

The blood phospholipid content of the normal group was significantly increased to 304.83 ± 116.26mg / dl in the control group compared to 130.00 ± 19.19mg / dl. 139.83 ± 18.61mg / dl showed a significant synergistic inhibitory effect compared to the control. The positive comparison drug, lovastatin 100mg / kg, had no synergistic inhibitory effect at 310.67 ± 117.82mg / dl, but it was not significant (see Table 4).

Effects of JH001 on Serum Phospholipid Level in Hyperlipidemic Rats Induced by Triton WR-1339 Group Dose No. of Serum phopholipid protection (mg / kg, p.o.) animals levels (mg / dl) (%) Normal - 6 130.00 ± 19.19 - Control - 6 304.83 ± 116.26 ## 100% Sample A 100 6 153.17 ± 14.88 ** 86.7% Sample B 1,000 6 139.83 ± 18.61 ** 94.4% Lovastatin 100 6 310.67 ± 117.82 -3.3%

* Each value is the mean ± mean error of six animals.

* Phospholipid inhibition is a% value calculated as 100x (control value-value of control group) / control value-value of normal group).

# Valid numeric ranges for normal group (#: p <0.05, ##: p <0.01 and ###: p <0.001)

* Significant range of numbers for the control group (*: p <0.05 and **: p <0.01)

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

4. HDL-cholesterol content in blood

The blood HDL-cholesterol content of the normal group was reduced to 51.17 ± 13.54mg / dl in the control group compared to 62.83 ± 10.15mg / dl, but there was no significance. In the mg-administered group, 69.17 ± 15.07mg / dl showed a decreased inhibitory effect compared to the control group, but it was not significant. The positive comparison drug lovastatin 100mg / kg group showed a decrease inhibitory effect of 55.00 ± 16.83mg / dl, but it was not significant (see Table 5).

Effects of JH 004 on Serum HDL-cholesterol Level in Hyperlipidemic Rats induced by Triton WR-1339 Group Dose No. of Serum HDL-cholesterol protection (mg / kg, p.o.) animals levels (mg / dl) (%) Normal - 6 62.83 ± 10.15 - Control - 6 51.17 ± 13.54 100% Sample A 100 6 63.67 ± 12.85 107.2% Sample B 1,000 6 69.17 ± 15.07 154.4% Lovastatin 100 6 55.00 ± 16.83 32.8%

* Each value is the mean ± standard deviation of six animals.

* HDL-cholesterol inhibition value is a% value calculated as 100x (control value-value of control group) / control value-value of normal group).

# Valid numeric ranges for normal group (#: p <0.05, ##: p <0.01 and ###: p <0.001)

* Significant range of numbers for the control group (*: p <0.05 and **: p <0.01)

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

5.LDL-cholesterol content in blood

The blood LDL-cholesterol content in the normal group was significantly increased to 42.50 ± 18.73mg / dl in the control group compared to 7.17 ± 1.47mg / dl, and in the experimental group, J.H. In the administration group, 24.00 ± 10.75mg / dl showed a synergistic inhibitory effect compared to the control group, but it was not significant. The positive comparison drug lovastatin 100mg / kg group showed 98.17 ± 46.55mg / dl and showed no synergistic inhibitory effect (see Table 6).

Effects of JH1004 on Serum LDL-cholesterol Level in Hyperlipidemic Rats induced by Triton WR-1339 Group Dose No. of Serum LDL-cholesterol protection (mg / kg, p.o.) animals levels (mg / dl) (%) Normal - 6 7.17 ± 1.47 - Control - 6 42.50 ± 18.73 ### 100% Sample A 100 6 25.17 ± 15.17 49.1% Sample B 1,000 6 24.00 ± 10.75 52.4% Lovastatin 100 6 98.17 ± 46.55 * -1.6%

* Each value is the mean ± standard deviation of six animals.

* The LDL-cholesterol inhibition value is a% value calculated as 100 × (control value-value of control group) / control value-value of normal group).

# Significant number range for normal group (#: p <0.05, ##: p <0.01 and ###: p <0.001)

* Range ranges for controls (*: p <0.05 and **: p <0.01)

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

6. Blood AST (GOT) Content

The blood AST content of the normal group was 164.17 ± 39.37mg / dl in the control group compared to 187.83 ± 42.82mg / dl, and the experimental group was 169.00 ± 22.87mg / dl in the JH1004-100mg group and 166.33 ± in the JH1004-1,000mg group. It was reduced to 34.75 mg / dl compared to the control, but there was no significance. The positive comparison drug lovastatin 100mg / kg was reduced to 143.67 ± 20.02mg / dl but was not significant (see Table 7).

Effects of JH1004 on Serum AST Level in Hyperlipidemic Rats induced by Triton WR-1339 Group Dose No. of Serum AST (mg / kg, p.o.) animals levels (mg / dl) Normal - 6 187.83 ± 42.82 Control - 6 164.17 ± 39.37 Sample A 100 6 169.00 ± 22.87 Sample B 1,000 6 166.33 ± 34.75 Lovastatin 100 6 143.67 ± 20.02

* Each value is the mean ± standard deviation of 6 animals

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

* AST (SGOT); Asparate aminotranferase activites.

7.ALT (GPT) content in blood

The blood ALT content of the normal group increased to 66.83 ± 11.70mg / dl in the control group compared to 57.50 ± 13.66mg / dl, but it was not significant.The experimental group was 47.83 ± 12.56mg / dl in the JH1004-100mg group and JH1004-1,000mg group. 44.50 ± 8.17 mg / dl showed a significant decrease compared to the control. The positive comparison drug lovastatin 100mg / kg was increased to 67.67 ± 18.13mg / dl but was not significant. (See Table 8)

Effects of JH1004 on Serum ALT Level in Hyperlipidemic Rats induced by Triton WR-1339 Group Dose No. of Serum ALT (mg / kg, p.o.) animals levels (mg / dl) Normal - 6 57.50 ± 13.66 Control - 6 66.83 ± 11.70 Sample A 100 6 47.83 ± 12.56 * Sample B 1,000 6 44.50 ± 8.17 ** Lovastatin 100 6 67.67 ± 18.13

* Each value is the mean ± standard deviation of six animals.

Normal: Non-killing group.

Control: treated with triton wr-1339.

Sample A: Group administered orally with JH1004 100mg / kg.

* Sample B: JH1004. Group administered orally at 1,000 mg / kg.

* ALT (SGPT); Alanine aminotranferase activites.

In the serum, the Triton WR-1339 treated control group showed higher values than the untreated normal group for ALT enzyme activity, and the Triton WR-1339 treated control group showed lower values for the AST enzyme activity than the untreated normal group. These enzymes are normally present in a small amount in the blood, but when the liver cells are damaged, a large amount flows into the blood and the concentration of the blood increases. Significantly elevated levels are typically seen in acute hepatocellular injury (e.g. viral, weak, ischemic hepatitis), while moderate elevations may be seen in various conditions (e.g., acute or chronic hepatocellular injury, invasive disease, biliary atresia). Can be. ALT is generally more sensitive to viral hepatitis than AST, and in alcoholic liver disease, AST is significantly elevated than ALT, typically with a ratio of AST / ALT greater than or equal to between liver cell necrosis and blood levels on liver biopsy. There is little proportional relationship and the elevated absolute value in acute liver disease has little to do with prognosis. In acute liver disease, ALT is elevated or higher than AST, whereas in chronic liver disease, AST may be higher than ALT.

Therefore, JH 1004 group was found to have good anti-hyperlipidemic effect in Triton WR-1339-induced experimental hyperlipidemic condition model rats.

8. Significance of experimental items

1) Total cholesterol (TC): Significant differences were observed between normal and control groups. JH1004-100mg group showed 81.8% TC and JH001-1,000mg group showed 83.1% TC synergistic effect. The dose-dependent inhibition of TC was found. The lovastatin 100 mg / kg group had an increase in TC of 31.9% compared to the control group, but it was not significant.

2) triglyceride (TG): Significant differences were observed between normal and control groups. JH1004-100mg-treated group showed 89.0% TG synergistic inhibitory effect and 93.4% of JH1004-1000mg-treated group. It can be seen that it suppresses TG dependently. The lovastatin 100mg / kg group showed 1.7% higher TG inhibition than the control group, but there was no significant difference.

3) phospholipid: There was a significant difference between normal and control group, and compared with the control group, JH1004-100mg group showed 86.7% and JH1004-1000mg group showed 94.4% synergistic inhibitory effect. In the lovastatin 100mg / kg group, the phospholipid level was increased by 3.3% compared to the control group, but it was not significant.

4) HDL-cholesterol: There was no significant difference between normal group and control group. Compared with the control group, JH1004-100mg group showed 107.2% HDL-cholesterol reduction inhibitory effect of 154.4%. There was no significant. The lovastatin 100mg / kg group had 32.8% HDL-cholesterol reduction inhibitory effect compared to the control group, but it was not significant.

In hyperlipidemia, the content of high density lipoprotein-cholesterol (HDL-C) in the blood lipoprotein is very important. In other words, HDL-C content is inversely related to leprosy rate in atherosclerotic diseases including coronary artery disease, and HDL is known as lipoprotein in the defense mechanism of atherosclerosis, which is an excess of cholesterol accumulated in peripheral tissues in the atherosclerotic defense mechanism. It can be seen that HDL is involved in the route to draw and transport to the liver.

5) LDL-cholesterol: There was a significant difference between normal and control group, compared with control group, 49.1% in JH1004-100mg group and 52.4% in JH1004-1,000mg group, but LDL-cholesterol synergistic effect was significant. There was no. The lovastatin 100mg / kg group had an increase in LDL-cholesterol level of 1.6% compared to the control group, but it was not significant.

The liver is composed of VLDL and secreted into the serum along with the exogenous lipid components obtained from chylomicron and the cholesterol, triglyceride, phospholipid and apo protein synthesized by the liver. VLDL is metabolized into LDL, which increases the proportion of small cholesterol slowly by lipoprotein lipase or cholesteryl ester triglyceride converting enzyme. Some of the LDL is incorporated into peripheral tissues through its specific receptor, the LDL receptor, and used as a cholesterol source, but 60 to 80% is resorbed by the liver LDL receptor. Elevated serum LDL-C levels are known to be the most important cause of atherosclerotic disease, so lowering LDL-C levels is important in treating hyperlipidemia.

6) AST: 169.00 ± 22.87mg / dl in the JH1004-100mg group and 166.33 ± 34.75mg / dl in the JH1004-1000mg group, which was not significant. The positive comparison drug lovastatin 100mg / kg was decreased to 143.67 ± 20.02mg / dl but was not significant.

7) ALT: The experimental group showed 47.83 ± 12.56mg / dl in the JH1004-100mg group and 44.50 ± 8.17mg / dl in the JH1004-1,000mg group. The positive comparison drug lovastatin 100mg / kg was increased to 67.67 ± 18.13mg / dl but was not significant.

As seen from the above experimental examples, it can be seen that the symptoms of hyperlipidemia or high cholesterol when drinking the present invention can be more effectively improved.

In the above examples and experimental examples, it was described that the composition of the concentrate to improve the symptoms of hyperlipidemia and high cholesterol using herbal medicines such as hawthorn, red ginseng, drizzle, zhao ga, kill, persimmon, licorice, Schisandra chinensis.

In addition, although the concentrate of the present invention has been described above, the concentrate obtained by the above method may be used for beverages (soft drinks, drink preparations, etc.), ice creams, dairy products, noodles, sauces, chewing gum, confectionery ( Candy, jelly, and granules can be added and used in the process of preparing the concentrate, wherein the concentration of the concentrate is preferably 1 to 10% by weight.

For example, 0.5% by weight of honey, 2.0% by weight of pear juice, 1.0% by weight of sugar, 3.0% by weight of high fructose, 0.1% by weight of citric acid, 0.1% by weight of stevioside, 0.05% by weight of sodium benzoate, 88.4% by weight of purified water By adding the concentrate obtained as described above, it is possible to obtain a beverage for improving hyperlipidemia, wherein the participation content range of the concentrate can be added or subtracted within the range of 1 to 10% by weight.

The manufacturing process of the beverage is carried out by powder raw material measuring process, liquid raw material measuring process, mixing input process, mixing process, canning process, sterilization operation among the raw materials.

According to the present invention as described above, it is easy to manufacture as a herbal medicine material, anyone can easily drink anywhere, in particular, it is effective in improving hyperlipidemia and hypercholesterol symptoms during long-term drinking.

Claims (6)

Concentrate for improving hyperlipidemia and hypercholesterolemia caused by herbal extracts by depressurizing and extracting herbal extracts from Sansa, Dansam, Dried Sewage, Zhao-gai, killing, and extracting the herbal ingredients of persimmon soup, licorice and Schisandra chinensis with water. The concentrate for improving hyperlipidemia and high cholesterol by herbal medicines, characterized in that consisting of the following component ratios. Hawthorn 5 to 65% by weight; Salviae 5-20%; 5-20% by weight 5-15 weight percent meridian; Kill 5-15%; 5-10 wt% of; Licorice 5-10% by weight and Schisandra chinensis 5% by weight Sansa, Dansam, Red Sewage, Zhao, killing, putting the raw materials of persimmon soup, licorice and Schisandra chinensis into a prepared container; Injecting only pure water corresponding to 20 times the total weight ratio of the herbal ingredient formulation into the container; Pouring the herbal formulation mixed with water at 95-100 for 2 hours; And Method of producing a concentrate for improving hyperlipidemia and high cholesterol by herbal medicines, characterized in that it comprises the step of obtaining a concentrated liquid by filtration under reduced pressure after filtering the filter fluid with a filter or sieve (net) having a scale of 200 mesh . The method of claim 3, further comprising a freeze-drying step for lyophilizing the concentrate and pulverizing the concentrate after the step of obtaining the concentrate. The method of claim 3, wherein the herbal medicine material is made of the following ingredient ratios. Hawthorn 5 to 65% by weight; Salviae 5-20 wt%; 5-20% by weight 5-15 weight percent meridian; Kill 5-15%; 5-10 wt% of; Licorice 5-10% by weight and Schizandra 5 wt% Beverages (soft drinks, drink preparations, etc.), ice creams, dairy products, noodles, sauces, chewing gum, confectionery (candy, jelly, granules) Use of the concentrate for improving hyperlipidemia and high cholesterol by adding the obtained concentrated solution 1 to 10% by weight.